However, although the role of SCD has been investigated in solid cancer models, translational progress of SCD as a therapeutic target has been hampered by the lack of clinical-grade inhibitors with only one recent report, using the SCD inhibitor YTX-7739 in glioblastoma presenting survival benefit of pharmacological SCD inhibition in an animal solid tumor model [4]. The gene discussed is SCD; the disease is glioblastoma.